CASE DESCRIPTION
================

A 17-year-old male patient presented recurrent episodes of thrombotic microangiopathy (TMA), characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ damage.

The first episode occurred at 6 months of age with arterial hypertension, anemia, thrombocytopenia and kidney injury that required dialysis. After plasma infusions, he recovered renal function and was discharged. At the age of 2 years, he presented a new episode of TMA, but recovered faster with plasma infusions and did not require dialysis. At the age of 14 years, he returned with severe hypertension, increase in serum creatinine and fluctuation in platelet count. Two years later, a renal biopsy demonstrated chronic TMA ([Figure 1](#sfz043-F1){ref-type="fig"}).

![First Renal Biopsy at age 16 years (before treatment with eculizumab), February 6th, 2016. (**A**) - Reduplication of glomerular basement membrane and mesangiolysis - arrow (silver, x400); (**B**) - Corrugated and reduplication of glomerular basement membrane (Gömöri's trichrome, x400); (**C**) - Intimal thickening of small artery (periodic acid -Schiff, x400); (**D**) - Immunofluorescence microscopy shows arterial wall staining for C3 (x400).](sfz043f1){#sfz043-F1}

After secondary causes for TMA were excluded and a normal activity of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 ruled out thrombotic thrombocytopenic purpura, the diagnosis of atypical hemolytic uremic syndrome (aHUS) was made.

Eculizumab was started in the Food and Drig Administration-approved regimen for atypical Hemolytic Uremic Syndrome (aHUS). After 18 months of treatment, despite hematological improvement, the patient persisted with hypertension (four classes of anti-hypertensive drugs), with progressive decline in renal function and increase in proteinuria. Genetic analysis (Centogene^®^, Rostock, Germany) was positive for an homozygous deletion in the diacylglycerol kinase epsilon (*DGKe*) gene---p.356AspLysfs\*6 (c.1069_1071del), a new mutation in the last amino acid of the catalytic domain of the protein, considered pathogenic according to American College of Medical Genetics classification \[[@sfz043-B1]\]. A second renal biopsy was performed with worsening of interstitial fibrosis and severe vasculopathy ([Figure 2](#sfz043-F3){ref-type="fig"}). Eculizumab was stopped and 3 months later kidney function was stable ([Table 1](#sfz043-T1){ref-type="table"}).

![Second Renal biopsy: After 18 months of eculizumab treatment- April 4th, 2018. (**A**) Corrugated and reduplication of glomerular basement membrane and mesangial expansion -(silver, x400). (**B**) Glomerular mesangial expansion (hematoxylin and eosin, x400). (**C**) Intimal thickening of small artery (silver, x400). (**D**) Immunofluorescence microscopy shows arterial wall staining for C3 (x400).](sfz043f2){#sfz043-F2}

###### 

Evolution of hematological and renal parameters of the index patient before and after complement blockade with eculizumab

                                      Date                                                                                                                                                                                                                                                                                
  -------------------------- ----------------------- ------------------------ ------------------ -------------- ----------------------------- ----------------------- ---------------------- ---------------------- ----------------- ------------- ----------------------------------- --------------------------------- ----------------
  Time point                  First mani- festation   Second mani- festation   Resume follow-up   First biopsy   First eculi- zumab infusion   First month treatment   Ongoing eculi- zumab   Ongoing eculi- zumab   Genetic testing                 Second biopsy and eculizumab stop   Follow-up after eculizumab stop   Last follow-up
  Hb (mg/dL)                                                                                          12.4                  11.2                       10.9                                                               12.2                                                                        10.6                
  Platelets (×10^3^/mm^3^)                                                                            199                    130                        148                                                                203                                                                         178                
  LDH (U/L)                                                                                           166                    169                        154                                                                182                                                                                            
  SCr (mg/dL)                                                                                         1.8                    2.4                        2.0                                                                2.4                                                                         2.3                
  Proteinuria                                                                                                                3+                                                                    1.1 g/24 h          3.6 g/24 h      2.4 g/ 24 h                                                 2.2 g/24 h             

Manif, manifestation; ecu, eculizumab; LDH, lactic dehydrogenase (upper normal limit 248 U/L); Hb, hemoglobin.

His parents are consanguineous and carry the variant DGKe p.356AspLysfs\*6 (c.1069_1071del) in heterozygosis, as does his younger sister ([Figure 3](#sfz043-F3){ref-type="fig"}). They are being followed up and the father presents hypertension and a creatinine of 1.3 mg/dL, with no proteinuria.

![Family Pedigree. Index case (II-1) developed first symptoms of aHUS at six months. His genetic diagnosis prompted the analysis of the family members, uncovering the presence of the variant p.356AspLysfs\*6(c.1069_107del) in all of them.](sfz043f3){#sfz043-F3}

DISCUSSION
==========

aHUS is characterized by thrombosis in the microvasculature. The central pathophysiology in at least 50--60% of patients is the overactivation of the alternative complement pathway. The introduction of the terminal complement blocker eculizumab changes the perspective of these patients. However, 30--40% of patients do not have an identified genetic variant in complement genes \[[@sfz043-B2]\].

Lemaire *et al*. \[[@sfz043-B3]\] reported recessive loss-of-function mutations in DGKe as the cause of aHUS in some pediatric cases presenting in the first year of life, establishing a different pathophysiological mechanism for TMA that does not involve complement.

In 2017, Azukaitis *et al*. \[[@sfz043-B4]\] analyzed data of 44 patients with DGKe nephropathy, and the authors presented a case for whom eculizumab was not able to prevent TMA relapse. Two patients who had relapses of TMA while on eculizumab had been published by Lemaire *et al*. \[[@sfz043-B3]\], and case reports of eculizumab and DGKe are summarized in [Table 2](#sfz043-T2){ref-type="table"}. Initially, DGKe TMA was considered a complement independent condition. Recent assays support the concept of complement activation (C3 consumption and deposition on biopsy, alternative pathway activation) in a subset of patients, and there are a few patients who also present mutations in complement regulator genes. It still remains unclear whether complement activation is a primary or secondary event in DGKe nephropathy, and which patients could benefit from complement blockade. In Azukaitis *et al*.'s \[[@sfz043-B4]\] review, 16 patients recovered completely without specific therapy, and only 1 progressed to end-stage renal disease.

###### 

Case reports of patients with TMA and DGKe mutation treated with eculizumab

  References                                                  Number of patients   Age at treatment   Genetic findings                                                                             Response to eculizumab
  ----------------------------------------------------------- -------------------- ------------------ -------------------------------------------------------------------------------------------- --------------------------------------------------------------
  Lemaire *et al*. \[[@sfz043-B3]\]                           13                   \<1 year           Homozygous and compound heterozygous mutations in DGKe                                       Two patients presented relapse of TMA during treatment
  Sanchez Chinchilla *et al*. \[[@sfz043-B5]\]                4                    \<1 year           Homozygous and compound heterozygous mutations in DGKe                                       Complete recovery in the patient with DGKe and C3 mutation
  Three patients also had mutations in thrombomodulin or C3                                                                                                                                        
  Miyata *et al*. \[[@sfz043-B6]\]                            1                    4 months           Compound heterozygous mutation in DGKe and a missense polymorphism in CFH                    Complete recovery with eculizumab after plasma-resistant TMA
  Negative anti-Factor H antibody                                                                                                                                                                  
  Basak *et al*. \[[@sfz043-B7]\]                             1                    17 years           Missense heterozygous variant in exon 2 DGKe and large homozygous deletion in CFHR1--CFHR3   Complete recovery

C3, complement component 3; CFH, complement factor H; CFHR1--CFHR3, complement factor H-related proteins 1 and 3; TMA, thrombotic micorangiopathy.

Our patient presented the first episode of TMA before 1 year of age as described in other reports. Both renal biopsies were in agreement with the description in Mele *et al*. \[[@sfz043-B8]\] of patients with DGKe mutations---histological features of chronic TMA, including endothelial cell swelling, glomerular hypercellularity, mesangial cell interposition within endothelial cells and split glomerular basement membrane. He presented with difficult-to-control hypertension, chronic kidney disease and proteinuria that did not improve after 18 months of eculizumab, probably because complement blockade was started in the late phase. Nevertheless, there was hematological improvement and we believe that the patient benefited from the treatment during his overt TMA presentation.

In conclusion, although eculizumab is the treatment of choice for aHUS, we point out the importance of genetic testing, especially in patients who present TMA before the first year of age. This is also true for patients who do not meet the expected outcomes with terminal complement blockade. Despite good outcomes reported in the literature in a few patients, in our patient with DGKe mutation, eculizumab did not prevent kidney progression or improved hypertension control.
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